The concept of cardiac remodeling implies a complex mixture of myocardial ischemia, and increased wall stress that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis. Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that can further affect the remodeling process. Despite advances in the management of heart failure, morbidity and mortality still present major health care issues in these patients. Statins (HMG Coenzyme A reductase inhibitors) play a key role in the management of ischemic heart disease. Recent studies indicate that statins may modulate cardiac remodeling by affecting signals that cause fibroblast growth, and myocyte hypertrophy and loss. In this paper we review the mechanisms of cardiac remodeling and the mechanisms of potential beneficial effects of statins on cardiac remodeling.
INTRODUCTION
Cardiac remodeling is defined as a genomic expression that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart [1] , whereby, the heart assumes a more spherical shape, along with an increase in left ventricular mass leading to worsening cardiac function and heart failure. At the cellular level, although most of the changes occur in the cardiac myocytes, the interstitium, collagen, fibroblasts, and coronary vasculature are equally involved in this process. Remodeling is associated with myocyte hypertrophy, myocyte loss from necrosis [2] or apoptosis [3] , as well as interstitial cell growth, especially fibroblast proliferation, leading to myocardial fibrosis [4] . Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that further adversely affect the remodeling process.
Cardiac remodeling can occur following any form of cardiac injury, but most of our understanding of the pathophysiology of this process came from animal models of remodeling following myocardial infarction (MI) or ischemia. However, remodeling can also occur in the setting of pressure overload as in hypertension and aortic stenosis, or volume overload as in valvular regurgitation, along with disease states such as idiopathic cardiomyopathy or myocarditis.
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involved in this process has evolved. Therapeutic interventions designed to counteract the neurohormonal changes, and hence the remodeling processes, have resulted in a substantial reduction in mortality and morbidity.
Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors have a well-established role in the management of coronary artery disease (CAD) through effects that may extend beyond their cholesterol lowering effects. Recently, in animal models of heart failure induced by coronary artery ligation, statin use has been shown to have beneficial effects in improving ventricular function through modulation of the cardiac fibrosis [6, 7] .
This review focuses on some of the pathways involved in ventricular remodeling and the potential mechanisms by which statins influence the cardiac remodeling process.
RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM AND CARDIAC REMODELING
The rennin-angiotensin-aldosterone-system (RAAS) plays a key role in the remodeling process from beginning of heart failure to the end sequel (Fig. 1) . Renin is produced in the kidney and it acts on angiotensinogen released by the liver to form angiotensin I. This in turn is cleaved by the angiotensin converting enzyme (ACE) to produce angiotensin II (Ang II), the major effector peptide. Ang II acts through many of its receptors; of these, type 1 (AT1) and type 2 (AT2) receptors have been well studied. Ang II is also formed in vascular tissues including the heart [8] , which has implications in the pathogenesis of cardiac remodeling. This concept is supported by observational studies that showed markedly increased levels of ACE in the remaining viable myocytes after MI in human myocardial tissue [9] , and also the increased expression of AT 1 receptor mRNA in noninfarcted areas, after MI in an animal model [10] . This suggests an early involvement of the RAAS in the remodeling process after MI.
Several animal studies have shown that Ang II is a critical mediator of cardiac myocyte hypertrophy, cardiac fibroblast proliferation and collagen synthesis [11] , leading to cardiac fibrosis. This effect is mediated through AT1 receptor activation in fibroblasts derived from cardiomyopathic hearts [12] . Yang and Mehta [13] showed intense expression of AT1 receptor activation in isolated rat hearts subjected to ischemia-reperfusion injury. Acute cardiac injury can be attenuated by AT1 receptor blockers, antisense directed at AT1 receptor mRNA as well as ACE inhibitors [14] . Ang II also exerts profibrotic effects in human cardiac fibroblasts via an increase in plasminogen activator inhibitor-1 (PAI-1), transforming growth factor-β1 (TGF-β1) [15] , and endoglin receptor type-3 expression [16] , the latter appears to mediate the profibrotic effect of TGF-β1. These effects are mediated via AT1 receptor activation. Ang II is also a potent stimulator of pro-inflammatory cytokines [17] , such as TNF-α.
It is of interest that the changes in myocardial collagen content correlate with the serum concentration of C-terminal propeptide of procollagen type 1 (PIP), which is a marker or collagen type 1 synthesis [18] , and also with the collagen type 1 pyridinoline cross-linked C-terminal telopeptide (CITP), which is a marker of collagen degradation. The AT1 receptor blocker losartan, a prototype of agents known as angiotensin receptor blockers (ARBs), reduced serum PIP levels and increased serum CITP levels in hypertensive patients with cardiac fibrosis in one study [19] . This suggests that ARBs can stimulate the degradation of collagen at least in hypertensive patients.
Aldosterone, whose secretion is stimulated by Ang II, also plays an important role in cardiac remodeling and the pathophysiology of heart failure [20] . The heart contains receptors for mineralocorticoids, and can extract aldosterone after MI, leading to left ventricular remodeling [21] . Secondary hyperaldosteronism seen in advanced heart failure has been shown to induce myocyte hypertrophy, interstitial collagen formation and cardiac fibrosis [22] . Despite treatment with ACE inhibitors, an aldosterone "escape" phenomenon has been demonstrated in patients with heart failure [23] ; this phenomenon can be attributed to Ang II formation through a non-ACE pathway [24] , or through Ang II-independent stimulation of aldosterone production. The Ang II-independent stimuli for aldosterone release include volume depletion, activation of the sympathetic nervous Fig. (1) . This picture shows a critical role of angiotensin II (Ang II) from the early to late stages of heart failure. During loss of myocytes, as during myocardial ischemia, a low cardiac output state is established, which causes the release of Ang II. Ang II is a pro-inflammatory molecule, which results in the release of metalloproteinases (MMPs), which cause collagen degradation, resulting in myocyte slippage leading to wall thinning and chamber dilation. In the mid-stage of heart failure, Ang II stimulates the release of catecholamines, atrial and brain natriuretic peptides, and endothelin-I (ET-1). This, coupled with increased wall stress and local Ang II release, results in myocyte hypertrophy and heart failure. During the late stage of heart failure, Ang II induces TGFβ1 expression, which causes macrophage and fibroblast proliferation and collagen formation. This results in cardiac enlargement and fibrosis. system and catecholamine release and endothelin expression [25] . The beneficial effects of the aldosterone antagonist spironolactone come at least in part from reduction in fibrosis through competition for the cardiac mineralocorticoid receptors [26] .
In clinical studies, plasma Ang II, renin, and ACE levels correlate significantly with left ventricular mass and generally with patient outcome. Pfeffer and Braunwald [5] showed in a rat model of chronic ischemia that remodeling was directly proportional to the infarct size. Later they demonstrated that ACE inhibition attenuated the remodeling process that translated into improved survival [27] .
Inhibition of RAAS with ACE inhibitors or ARBs can attenuate the remodeling process and result in improved patient survival [28] . This has been shown in a number of studies in both hypertensive [29, 30] , and post-MI patients [31] [32] [33] [34] [35] . The use of aldosterone antagonist in the RALES study [36] on top of standard medical therapy with ACE inhibitors in patients with advanced heart failure showed a 30% reduction in overall mortality.
STATINS AND THE RAAS
Blockade of the HMG-CoA reductase by statins disrupts the mevalonate pathway. Mevalonate is an important precursor of nonsteroidal isoprenoid compounds apart from cholesterol. Isoprenoids are involved in the growth and proliferation of cardiac smooth muscle cells [37] . The HMG CoA-mevalonate-GGPP pathway supplies prenyl groups to the members of the p21 Rac, Ras, or Rho families of lowmolecular-weight GTP-binding proteins .These G-proteins are essential for the intracellular signaling of Ang II AT1 receptors [37] . Statins decrease this potent cellular effect of Ang II [37] . Statins not only decrease the intracellular signaling of Ang II receptors but they also decrease the expression of AT1 receptors. Ichiki et al. [37] showed that HMG CoA reductase inhibitors reduced the expression of AT1 receptor mRNA in vascular smooth muscle cells. Various sites in the Ang II cascade leading to heart failure are shown in Fig. 2 .
Reactive oxygen species (ROS) are also thought to be involved in the pathogenesis of remodeling. ROS enhance proliferation of vascular smooth muscle cells, and induce apoptosis of endothelial cells [38] . Recent studies in our laboratory show that Ang II increases ROS formation in cardiac fibroblasts (Fig. 3) via the activation of AT1 receptors. Statins can decrease Ang II-induced release of ROS in the vascular smooth muscle cells through downregulation of AT1 receptor gene expression. Inhibition of ROS by statins results in a decrease in Rac1 activation as well as geranylgeranyl-dependent translocation of Rac1 from the cytosol to the cell membrane [39] .
In a study by Dechend et al. [40] ; treatment of transgenic rats with cerivastatin ameliorated Ang II-induced hypertension, cardiac hypertrophy, fibrosis, and remodeling independent of cholesterol reduction. Similar results were demonstrated with the use of lovastatin in cultured neonatal rat heart cells [41] . Inhibition of Ras/MAP kinase linked to the mevalonate pathway was thought to be the underlying mechanism.
The addition of statins to ACE inhibitors in patients with hypertension has been shown to confer additive benefit. A recent review by Singh and Mehta [42] highlighted the mechanisms by which dyslipidemia enhances RAAS activation, and Ang II promotes the adverse effects of dyslipidemia. Statins lower low density-lipoprotein (LDL) cholesterol and simultaneously attenuate many of the adverse effects of Ang II on cell biology. These effects of statins may complement the effects of ACE inhibitors and ARBs on cardiac remodeling.
SYMPATHETIC NERVOUS SYSTEM AND CARDIAC REMODELING
The sympathetic nervous system plays a critical role in supporting cardiac function in the early stages of heart failure, but in the later stages contributes to the pathogenesis and progression of cardiac remodeling (Fig. 4) . The end result of cardiac remodeling, namely heart failure, has been described as a sympatho-excitatory state. In this scenario, both α-and β-adrenergic receptors are activated, resulting in the stimulation of phospholipase C/protein kinase (PK) C or adenylyl cyclase/PKA signaling pathways, respectively.
In the early stages of heart failure, decreased cardiac performance causes activation of the sympathetic system leading to increased norepinephrine (NE) and epinephrine release [43] ; epinephrine through activation of the β 1 -adrenergic receptors causes an increase in heart rate and cardiac contractility, which leads to an increase in cardiac output and improved cardiac performance. This response designed to maintain near normal cardiac function is beneficial over the short-term; however, it ultimately results in worsening cardiac function. Mann et al. [44] showed a direct toxic effect of NE on cultured cardiac myocytes causing extensive loss of myocyte viability within days. These effects are mediated mainly through β-adrenergic receptors. These receptors have been implicated in myocardial necrosis and cardiac failure [45] . Both epinephrine and NE also induce apoptosis of endothelial cells. NE in particular promotes fibrosis by enhancing TGF-β1 expression [46] .
In addition, long-term adrenergic activation has been implicated in changes in gene expression of cardiac myocytes, especially in the β-adrenoceptor signaling [47] .
Until recently, α-adrenergic signaling was not considered to have a critical effect on the myocardium. Studies by Simpson et al. in embryonic cardiac myocytes demonstrated that α-adrenergic receptor stimulation leads to PKC activation, a powerful stimulus for myocyte hypertrophy [48, 49] . These early observations were validated in vivo by Lefkowitz et al. who demonstrated that modest increase in PKC signaling reproduced an increase in cardiac mass, myocyte cross-sectional area and expression of embryonic cardiac genes [50] .
There is growing evidence that nitric oxide (NO) is also an important player in neurohormonal excitation. NO release by the endothelium regulates blood flow [51] , inflammation and platelet aggregation [52] . The hypothalamus is involved in regulating sympathetic outflow, and any change in NO synthase (NOS) in these areas is reflected in the peripheral sympathetic activity [53] . Evidence in favor of this hypothesis has been provided by studies in an animal model of heart failure that showed central NOS gene downregulation [54] . There is also some evidence that Ang II is also involved along with inducible NOS (iNOS) activation in the activation of sympathetic nervous system. Liu and Zucher showed that both a loss of NO and an increase in Ang II are required for sustained increases in sympathetic nerve activity in a pacing-induced heart failure model in rabbits [55] .
Early evidence of reverse remodeling through modulation of the neurohormonal system came from McDonald and his colleagues [56] , who showed that the use of β-blockers and ACE inhibitors can in a synergistic fashion reverse remodeling in a canine model of discrete myocardial damage. Several clinical trials have been conducted recently to evaluate the effects of pharmacologic approach to left ventricular remodeling; β-blockers not only improve left ventricular function, but also reduce left ventricular volume and myocardial stress [57] .
STATINS AND THE SYMPATHETIC NERVOUS SYSTEM
The potential beneficial effects of statins have been evaluated in animal models of heart failure. Pliquett et al. [58] used simvastatin to treat normolipidemic rabbits with heart failure, and found that statin use lowered plasma NE concentrations. Simvastatin also decreased resting renal sympathetic nerve activity and normalized baroreflex sensitivity in rabbits with heart failure. Similar observations were made in humans, wherein intensive statin treatment normalized baroreflex sensitivity [59] , supporting the concept of a sympatholytic effect of statins.
It is well known that statins can up-regulate eNOS expression [60, 61] , and up-regulation of eNOS can have a sympatholytic effect. Statins may alter NO release through several mechanisms, such as inhibiting the production of mevalonate and important isoprenoid intermediates, thereby inhibiting the isoprenylation of the small GTPase Rho -such as RhoA and Rac1-α which are molecular switches that regulate the growth and morphology of myocytes and fibroblasts, as well as the expression of eNOS [55] . Rac1 also regulates NADPH oxidase, which is a major source of ROS in cardiovascular tissues. Recent studies suggest that ROS may be involved in cardiac hypertrophy; and statins attenuate oxidative stress through inhibition of Rac1 [62] . Furthermore, statins may also increase eNOS activity through post-translational activation of the phosphatidylinositol 3-kinase/protein kinase Akt (PI3K/Akt) pathway and/or through an interaction with the heat-shock protein 90 (HSP90) [63] . The interaction between Ang II and NO has been previously elucidated. Statins can provide additional sympatheto-inhibitory effect by down regulating Ang II receptors, and enhancing NO release [64, 65] . Fig. (4) . Pro-inflammatory cytokines, such as TNFα and IL-6 act via specific receptors and induce cardiac myocyte hypertrophy and migration, apoptosis and necrosis, which results in ventricular remodeling and heart failure. Endothelins and insulin-resistance state (such as diabetes) act on specific receptors leading to cardiac myocyte hypertrophy and migration, apoptosis and necrosis, and subsequently heart failure. The release of epinephrine/norepinephrine and activation of the renin angiotensin aldosterone system (RAAS) act on specific receptors and mediate the steps leading to ventricular remodeling and heart failure.
Theses actions of statins on the adrenergic system may act in concert with adrenergic blocking drugs, ACE inhibitors and ARBs in attenuating cardiac remodeling. Some of the mechanisms by which statins attenuate the effect of catecholamine actions are shown in Fig. 2. 
ENDOTHELINS, CARDIAC REMODELING AND THE ROLE OF STATINS
Endothelins are a group of potent vasoconstrictor peptides; endothelin 1 (ET-1) is the predominant isoform that is believed to be the most potent vasoconstrictor known. ET-1 is synthesized from a precursor known as the prepro-ET-1 that is cleaved to form big ET-1 before it is converted to ET-1 [66] . ET-1 exerts its effects through ET A and ET B receptors [67] , on cardiac myocytes and fibroblasts. ET A receptors present in the atrial and ventricular myocardium mediate the effects of ET-1 on the heart. In experimental heart failure, ET B receptors are up-regulated and can mediate cardiac fibrosis [68] .
ET-1 levels are increased in patients with heart failure [69] . Although its expression in the myocardium could be adaptive in the initial stages of heart failure its overexpression eventually plays a maladaptive role leading to cardiac remodeling, by producing ventricular hypertrophy, myocardial necrosis and myocardial fibrosis [70] , which is believed to be mediated by proliferation and production of extracellular matrix (ECM) proteins and collagen synthesis (Fig. 4) [71] . ET-1 has also been found to stimulate the production of growth factors such as vascular endothelial growth factor (VEGF) [72] , and to potentiates the actions of platelet-derived growth factor (PDGF) [73] .
Thus, the modulation of the ET-1 or its receptors can affect the remodeling process. Even though recent clinical studies evaluating the effects of ET-1 receptor antagonists have failed to show any benefit in patients with heart failure, interest in modulating ET-1 and its receptors continues. Ang II has been shown to enhance ET-1 gene expression in cardiac rat fibroblasts through ROS release ( Fig. 1 and 2) , and these effects of Ang II can be blocked by ARBs [74] .
An experimental study showed that simvastatin can decrease the basal transcription rate of the prepro-ET-1 gene in bovine aortic endothelial cells [75] . These authors also showed a reduction of immunoreactive ET-1 in patients with heart failure treated with simvastatin or atorvastatin [76] . Hence statins can favorably modulate the effect of ET-1, thereby halting or attenuating the remodeling process.
INFLAMMATION, PROINFLAMMATORY CYTO-KINES AND CARDIAC REMODELING
Recent interest in the role of inflammation and proinflammatory cytokines stems from the observation that some aspects of heart failure, left ventricular dysfunction and pulmonary edema, can be explained through the biologic effects of proinflammatory cytokines, and that inflammatory mediators, such as TNF-α and IL-6, are elevated in patients with heart failure [77, 78] . The release of these cytokines is believed to play an important role in the progression of heart failure [79] [80] .
This concept of the role of inflammatory mediators in the progression of heart failure, the so-called "cytokine hypothesis" [81] originated from the observation of their toxic effects on the heart, leading to progressive left ventricular remodeling, through alteration in fetal gene expression, myocyte hypertrophy [82, 83] , and apoptosis [84] . In addition, the cytokine TNF-α has been shown to promote left ventricular remodeling through alterations in ECM causing left ventricular dilatation, related perhaps to the activation of matrix metalloproteinases (MMPs) [85] .
STATINS AND INFLAMMATION
Statins can reduce the levels of TNF-α, thus decreasing its deleterious effects on the heart [86] . Statins can also decrease the level of other proinflammatory cytokines like IL-6 [87] (Fig. 2) .
DIABETES, INSULIN RESISTANCE AND CARDIAC REMODELING
It is now well accepted that diabetes is a vascular disease. Diabetics have a greater risk of myocardial infarction and heart failure and have worse outcomes than non-diabetics [88, 89] . Diabetes plays a powerful role in smooth muscle cell growth and migration [90] , and can cause endothelial cell dysfunction [91] . In vitro experiments have shown that glucose enhances fibroblast proliferation and collagen synthesis [92] . Importantly Ang II [93] and aldosterone [94] are involved in myocyte apoptosis and cardiac remodeling in the presence of hyperglycemia. These data have been confirmed in in-vitro settings as well as in animal models. The common link between the RAAS, dyslipidemia and diabetes may be enhanced ROS synthesis and release and the subsequent breakdown of vasodilatory species NO [95] . It is noteworthy that eNOS expression is markedly reduced in tissues in the presence of hyperglycemia [96] . Diabetics also tend to have platelet activation either spontaneously or in response to exogenous stimuli. Excess of platelet released thromboxane A2 and growth factors in diabetics may also participate in the genesis and progression of heart failure [97] .
DIABETES AND STATINS
Statins improve cardiac remodeling via amelioration of myocyte hypertrophy, fibroblast proliferation and collagen synthesis [98] . This is not unexpected in view of their ROS inhibiting effect. Siegel et al. [99] showed that high glucose concentrations stimulated human arterial smooth muscle cell growth as well as mRNA levels of ECM proteins. Importantly cerivastatin decreased smooth muscle cell growth and gene expression of ECM proteins [99] , and the effect of tissue inhibitor of metalloproteinase-2 (TIMP-2) was also enhanced [99] . These observations points toward potential beneficial effects of statins in modifying the ventricular remodeling process in diabetics (Fig. 2) .
EXTRACELLULAR MATRIX REMODELING AND THE ROLE OF STATINS
The ECM of the heart comprises of a number of structural proteins forming a network of connective tissue that support the cardiac myocytes during contraction and relaxation and prevents myocyte slippage during contraction [100] . The ECM comprises mainly of fibrillar collagen, with smaller amounts of elastin, fibronectins, and laminin. Collagen type-1 is synthesized and secreted by fibroblasts and represents 85% of myocardial collagen followed by collagen type-3, which forms 11% of myocardial collagen [101] . Progressive left ventricular remodeling and dysfunction have been associated with significant changes in ECM in several animal and human studies. A substantial increase in "reactive" fibrillar collagen deposition, which leads to increased interstitial and perivascular fibrosis, has been observed in cardiac tissues of animals and humans with pressure-overload hypertrophy [102] . It is still unclear whether this "reactive" collagen deposition is triggered by myocardial ischemia, or is secondary to the local activation of trophic peptides [103] including Ang II, aldosterone, catecholamines, which leads to expression of TGF-β 1 , causing an increase in collagen type-1 [104] . This "reactive" fibrosis is the result of increased synthesis of collagen type-1 and -3 by fibroblasts, and/or decreased ECM degradation.
In volume-overload hypertrophy, ECM remodeling follows a different pathway in which cavity dilatation occurs because of myocyte hypertrophy and disruption of the collagen weave [105] . This is under dynamic control of two groups of proteins: the MMPs, which mediate the degradation of collagen, and their tissue inhibitors (TIMPs) that regulate the activity of MMPs [106] [107] . An increase in MMP activation and down-regulation of TIMPs are critical for the changes in collagen leading to chamber expansion in end-stage dilated cardiomyopathy in both animal models and humans [108] . Several studies have shown over-expression and activity of MMP-1, -2, -3, and -9, in animals and humans during the remodeling process after MI [109] . In spontaneous hypertensive rats, MMP activity has been shown to contribute to left ventricular dilatation and worsening of left ventricular function [110] .
Statins can inhibit MMP release and activity thereby preventing the destruction and, strengthening the ventricular ECM. A recent study in a murine model of post-infarct heart failure [111] , fluvastatin attenuated the increase in MMP levels after MI, along with an increase in the levels of TIMP-2; this was associated with an improvement in left ventricular performance, and a reduction in cardiac myocyte hypertrophy and interstitial fibrosis. Furthermore, there was a reduction in left ventricular end-diastolic pressure, as well as chamber size. This suggests a potential role of statins in reverse remodeling at least in animal models of post-MI heart failure. In another animal model of human hypertrophic cardiomyopathy [112] , the use of simvastatin for 12 weeks was associated with a reduction in interstitial collagen volume fraction, further supporting an effect of statin on regression of cardiac hypertrophy and fibrosis.
Many of the effects of statins such as inhibition of platelet aggregation and thrombogenesis [113] , reduction in inflammation [114] , and modulation of myocyte hypertrophy [115] and cardiac fibroblast growth [116] appears to be at least partially independent of LDL-lowering. All these effects have been confirmed in LDL-cholesterol free settings in vitro. Many of these effects are not altered by mevalonate; further supporting LDL-cholesterol lowering-independent effect of these agents.
CLINICAL DATA ON THE USE OF STATINS IN PATIENTS WITH CHF
Statins lower LDL-cholesterol and have been shown to have beneficial effects on reducing ischemic events and reducing the burden of ischemia [117, 118] ; these effects are related at least in part to their effect on plaque stability and endothelial dysfunction. Most of the earlier reports on the beneficial effect of statins on the evolution of heart failure in trials in CAD patients were subset post-hoc analysis, which suggested a possible benefit of statins primarily from ischemic cardiomyopathy.
In a post-hoc analysis from the Scandinavian Simvastatin Survival Study (4S study) [119] , long-term therapy with simvastatin reduced the incidence of heart failure as well as the mortality rate in a cohort of patients with CAD but without previous evidence of CHF. A mortality benefit was also seen in a post-hoc analysis from the Evaluation of Losartan In The Elderly Trial II (ELITE II) study [120] , where the group of patients on statin therapy had a 32% lower mortality rate compared with those not on a statin (10.6% vs. 17.6%).
The cholesterol and recurrent events (CARE) trial, which enrolled post-MI patients with mild hyperlipidemia, showed beneficial effects of pravastatin. In a subset of patients with reduced left ventricular systolic function (ejection fraction between 25-40%) post-MI, pravastatin use was shown to reduce cardiac events [121] .
A retrospective analysis of the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) study [122] showed that there was a 42% reduction in mortality in the group of patients on statin therapy compared with non-statin users over a 1.3 year of follow-up. This was irrespective of the etiology of heart failure (ischemic vs. non-ischemic).
Those aforementioned studies were retrospective, nonrandomized, subset analysis, but suggested a benefit of statins in patients with dyslipidemia and documented CAD in preventing their progression to heart failure, along with possible survival benefit.
These studies set the stage for some recent prospective randomized studies evaluating the benefit of statins in patients with non-ischemic cardiomyopathy and heart failure.
The first of these studies [123] enrolled 36 patients with symptomatic, non-ischemic, dilated cardiomyopathy. These patients were randomized to receive either low dose simvastatin or matching placebo. After 14 weeks of treatment with simvastatin, there was a noticeable improvement in functional capacity compared to placebo, which corresponded to improvement in left ventricular ejection fraction in the simvastatin group only (34±3 to 41±4%, P<0.05). Even thought this study did not evaluate the mechanism by which statins might have conferred the benefit, there was a positive correlation between the change in left ventricular ejection fraction and reduction in plasma levels of IL-6, TNF-α and brain natriuretic peptide. These observations suggest that statin-mediated improvement in cardiac function could be explained in part by modulation of the proinflammatory state.
Similar beneficial effects were observed in another recent small study [124] in patients with non-ischemic dilated cardiomyopathy. After 20 weeks of treatment; those randomized to cerivastatin had an improvement in the quality of life and exercise capacity when compared with placebo. This was associated with a trend towards improved left ventricular ejection fraction and endothelial function (forearm blood flow). The group of patients randomized to the statin had lower plasma concentrations of several inflammatory markers [(hsCRP), PAI-1 and TNF-α], which also suggests that the potential benefit of statin therapy on ventricular function might be related to its pleotropic effects, namely anti-inflammatory effects.
Based on these observations, further large randomized, double blinded studies are needed to support these potential beneficial effects of statins on left ventricular function, especially in patients with non-ischemic dilated cardiomyopathy. These studies should also address the mechanisms by which statins exert those effects, irrespective of their lipid-lowering effects or their beneficial effects on myocardial perfusion and coronary blood flow.
CONCLUSIONS
Cardiac remodeling is a complex mixture of neurohormonal imbalance, inflammation, and endothelial dysfunction that lead to impaired cardiac performance. And despite recent advances in the management of heart failure, this disease process still carries a high rate of morbidity and mortality.
HMG Coenzyme A reductase inhibitors (statins) are mainstay in the management of ischemic heart disease. Recent findings show that statins may have beneficial effects that extend beyond their antihyperlipidemic properties.
The studies reviewed in this paper clearly suggest a powerful role of statins in modulating neurohormonal changes leading to a set of complex, but inter-related, intracellular signals that reduce fibroblast growth, myocyte hypertrophy and loss, and formation of ECM proteins. These findings suggest a potential role for statins as a novel treatment option for patients with heart failure, irrespective of etiology.
